Literature DB >> 29982185

Hungry bone syndrome secondary to prostate cancer successfully treated with radium therapy.

Vishnu Vardhan Garla1, Sohail Salim1, Karthik Reddy Kovvuru1, Angela Subauste1.   

Abstract

A 50-year-old man with a history of prostate cancer with extensive bone metastasis and hypocalcaemia presented with muscle aches and cramps. Physical exam was significant for Chvostek's and Trousseau's sign. Laboratory assessment was consistent with profound hypocalcaemia. This was believed to be due to hungry bone syndrome secondary to advanced prostate cancer. He was treated with intravenous calcium, vitamin D and calcitriol. He also received three doses of radium223 therapy. After therapy, hypocalcaemic episodes resolved. Follow-up after 2.5 years showed continued resolution of hypocalcaemia. © BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  calcium and bone; endocrine system; prostate cancer; radiotherapy

Mesh:

Substances:

Year:  2018        PMID: 29982185      PMCID: PMC6040511          DOI: 10.1136/bcr-2018-225039

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

Review 1.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

2.  Severe hypocalcaemia associated with extensive osteoblastic metastases in a patient with prostate cancer.

Authors:  M I Fokkema; L J M de Heide; W D van Schelven; N A T Hamdy
Journal:  Neth J Med       Date:  2005-01       Impact factor: 1.422

3.  Severe hypocalcaemia because of osteoblastic prostate carcinoma metastases.

Authors:  Serkan Yener; Omer Demir; Ozhan Ozdogan; Baris Akinci; Sena Yesil
Journal:  Int J Clin Pract       Date:  2008-10       Impact factor: 2.503

4.  Refractory hypocalcaemia complicating metastatic prostatic carcinoma.

Authors:  Christopher Rizzo; Sandro Vella; Mario J Cachia
Journal:  BMJ Case Rep       Date:  2015-06-29

Review 5.  Radium-223 Therapy of Bone Metastases in Prostate Cancer.

Authors:  Sten Nilsson
Journal:  Semin Nucl Med       Date:  2016-09-15       Impact factor: 4.446

6.  Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen.

Authors:  M Iwamura; J Hellman; A T Cockett; H Lilja; S Gershagen
Journal:  Urology       Date:  1996-08       Impact factor: 2.649

Review 7.  Characterising the castration-resistant prostate cancer population: a systematic review.

Authors:  M Kirby; C Hirst; E D Crawford
Journal:  Int J Clin Pract       Date:  2011-11       Impact factor: 2.503

8.  Hypocalcemia with osteoblastic metastases in patient with prostate carcinoma. A cause of secondary hyperparathyroidism.

Authors:  R C Smallridge; H L Wray; M Schaaf
Journal:  Am J Med       Date:  1981-07       Impact factor: 4.965

9.  Osteomalacia associated with prostatic cancer and osteoblastic metastases.

Authors:  U M Kabadi
Journal:  Urology       Date:  1983-01       Impact factor: 2.649

10.  Hypocalcemia in patients with prostate cancer.

Authors:  S C Kukreja; A Shanmugam; T E Lad
Journal:  Calcif Tissue Int       Date:  1988-12       Impact factor: 4.333

View more
  2 in total

Review 1.  Nuclear and Radiological Emergencies: Biological Effects, Countermeasures and Biodosimetry.

Authors:  Elena Obrador; Rosario Salvador-Palmer; Juan I Villaescusa; Eduardo Gallego; Blanca Pellicer; José M Estrela; Alegría Montoro
Journal:  Antioxidants (Basel)       Date:  2022-05-31

Review 2.  Severe and refractory hypocalcaemia secondary to osteoblastic bone metastases in bladder signet ring carcinoma: A case report and literature review.

Authors:  Wanling Zeng; Du Soon Swee
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.